1. Introduction {#sec1}
===============

Breast cancer is a common medical problem and one of the leading causes of death among malignant conditions in women worldwide \[[@B1]\]. The incidence of breast cancer varied geographically. In Thailand it is the leading cancer among females with continuously increasing trend. The incidence increased from 37.9 in 2007 to 53.8 per 100000 population in 2011. The mortality also rose from 6.8 to 8.4 per 100000 population in the corresponding years \[[@B2]\].

Despite medical progresses in diagnosis and treatments in the past 10 years, recurrence after complete treatment was still common, both locoregional (27%) and distant (11%) \[[@B3], [@B4]\]. Survival and mortality of breast cancer varied from study to study \[[@B3], [@B5]\], and the most common cause of death was distant metastasis \[[@B5]\].

One of the most challenging tasks in managing breast cancer cases was disease prognostication of patients who were likely to have recurrence as prompt detection of recurrence may save the patients\' life or increase the survival time \[[@B6]\]. This should be done by risk evaluation of recurrence based on knowledge, genetics, molecular, biochemical sciences, and cytology \[[@B7]\]. With medical resource limitation, clinicians in poor developing countries were forced to manage patients with additional treatments, in which many cases might have been unnecessary, resulting in overtreatment \[[@B8]\].

Previous study mentioned demographic, pathological characteristics, hormone receptors, and types of treatment as the main prognostic factors for recurrence and survival of patients with breast cancer and most studies were done in developed countries \[[@B9], [@B10]\]. Whether these characteristics would be similar in poor developing countries is still inconclusive \[[@B11]\]. Very few studies have demonstrated whether the prognostic characters for different types of disease progression are different.

We conduct the present study to identify patients characteristics that may be used by clinicians as prognostic determinants for breast cancer progression, locoregional recurrence, distant recurrence, and death. Clinicians may use these determinants to help disease prognostication or to help guiding patient managements or monitoring.

2. Subject and Methods {#sec2}
======================

2.1. Subject and Setting {#sec2.1}
------------------------

The 5-year medical files of women with documentary confirmed breast cancer diagnosis from two university affiliated hospitals in Lampang and Uttaradit in the north of Thailand during 2006 and 2010 were reviewed. We assembled a cohort of patients who were still free of locoregional or distant recurrence. These patients were documentary traced for local, distant recurrence and death from breast cancer.

2.2. Data Sources and Collection {#sec2.2}
--------------------------------

### 2.2.1. Key Information {#sec2.2.1}

The focusing study characteristics included patient characteristics, age, types of surgery; pathological characteristics, tumor size, histological type, histological grade, stage, dissected axillary lymph nodes, positive axillary lymph nodes, and lymphovascular invasion (LVI); receptor status, ER receptor, PR receptor, and HER2 receptor; and types of treatments, radiotherapy, hormonal therapy, and chemotherapy. Main clinical outcomes of interest, locoregional recurrence, distant recurrence, and death, were verified from medical registry. Survival status of patients who lost to followup was also verified by civil database retrievable from the Ministry of Internal Affairs and through prepaid postcard or direct contact through telephone.

2.3. Data Analysis {#sec2.3}
------------------

The patient characteristics were compared among the three different types of disease progression (locoregional recurrence, distant recurrence, and death from breast cancer). Prognostic indicators for each of the three clinical outcomes were analyzed as univariable and multivariable hazard ratio by stratified Cox\'s regression based on Lunn & McNeil\'s methods, in which multiple prognostic characteristics could be computed for multiple types of outcomes in only one single regression model \[[@B12]\]. The direction of significant prognostic characteristics were presented and summarized.

2.4. Ethical Approval {#sec2.4}
---------------------

This retrospective data analysis was approved by the research ethical committees of Lampang Hospital and Uttaradit Hospital and the research ethical committee of the Faculty of Medicine, Chiang Mai University.

3. Results {#sec3}
==========

A cohort of 829 patients with postoperative breast cancer was assembled. Most characteristics of patients with the three different clinical outcomes were significantly different, except for types of surgery, histological type, dissected axillary lymph nodes, and HER2 receptor ([Table 1](#tab1){ref-type="table"}).

Under the univariable analysis, most of the characteristics were significant ([Table 2](#tab2){ref-type="table"}). With multivariable analysis using stratified Cox\'s regression based on Lunn & McNeil\'s methods, there were only 7 significant characters. These characteristics were pathological tumor size \>2 cm, stage 3, positive axillary lymph nodes \>3, lymphovascular invasion (LVI), radiotherapy, hormonal therapy, and chemotherapy ([Table 3](#tab3){ref-type="table"}). Summarized direction of significant prognostic hazards in breast cancer ([Table 4](#tab4){ref-type="table"}).

Positive axillary lymph nodes \>3 (HR = 2.43, 95%  CI = 1.35--4.37,  *P* = 0.003) and presence of LVI (HR = 2.01, 95%  CI = 1.09--3.71,  *P* = 0.026) increased the hazard of locoregional recurrence.

Stage 3 (HR = 2.44, 95%  CI = 1.57--3.80,  *P* \< 0.001), positive axillary lymph nodes \>3 (HR = 1.79, 95%  CI = 1.10--2.93,  *P* = 0.020), and radiotherapy (HR = 2.40, 95%  CI = 1.50--3.84,  *P* \< 0.001) increased the hazard for distant recurrence, while hormonal therapy (HR = 0.44, 95%  CI = 0.30--0.65,  *P* \< 0.001) reduced the hazard.

For death from cancer, pathological tumor size \>2 cm (HR = 1.56, 95%  CI = 1.02--2.40,  *P* = 0.040), stage 3 (HR = 2.17, 95%  CI = 1.42--3.32,  *P* \< 0.001), positive axillary lymph nodes \>3 (HR = 2.16, 95%  CI = 1.36--3.43,  *P* = 0.001), and presence of LVI (HR = 2.87, 95%  CI = 1.69--4.87,  *P* \< 0.001) increased the hazard, while hormonal therapy (HR = 0.57, 95%  CI = 0.40--0.83,  *P* = 0.003) and chemotherapy (HR = 0.27, 95%  CI = 0.14--0.52,  *P* \< 0.001) reduced the hazard ([Table 3](#tab3){ref-type="table"}).

4. Discussion {#sec4}
=============

It was well realized that breast cancer is a heterogeneous disease originating from multiple somatic mutations, resulting in different risk for recurrence after treatment, which was commonly observed in patients with the same clinical stages \[[@B13]\].

4.1. Prognostic Characteristics for Locoregional Recurrence {#sec4.1}
-----------------------------------------------------------

### 4.1.1. Positive Axillary Lymph Nodes \>3 and Lymphovascular Invasion {#sec4.1.1}

There were 2 proposed hypotheses mentioning locoregional recurrence of breast cancer. Locoregional recurrence of breast cancer could be a sign of disseminated disease from the beginning \[[@B14], [@B15]\] and cancer cell might have already invaded into the blood stream when breast masses were detected or might have invaded through lymph vessels into the lymph nodes. On the other hand it might be associated with incomplete removal of cancer cell, resulting in residual tumor \[[@B16]\]. The present findings agreed with previous studies reporting positive axillary lymph nodes \>3 and lymphovascular invasion as prognostic factors for locoregional recurrence \[[@B9], [@B17]\].

4.2. Prognostic Characteristics for Distant Recurrence {#sec4.2}
------------------------------------------------------

### 4.2.1. Disease Stage 3 {#sec4.2.1}

Stage 3 breast cancer involved axillary lymph nodes. The chances of disseminating to other distant organs were increased \[[@B18]\]. This was also mentioned by other studies \[[@B19]\].

### 4.2.2. Positive Axillary Lymph Nodes \>3 {#sec4.2.2}

Distant dissemination of cancer cells occurred from spreading of disease from axillary lymph nodes involvement \[[@B20]\].

### 4.2.3. Radiation Therapy {#sec4.2.3}

After surgical removal of cancer, some patients would be irradiated as indicated. The association with an increase in risk of distant recurrence was confounded by indication or contraindication as mentioned above. It was likely that patients who were selected for irradiation were those with poor prognosis (confounded by indication). On the contrary, irradiation might stimulate production of miR-21 in the cell cycle resulting in radiation resistance and promoting cancer cell proliferation, which caused invasion and dissemination to other organs \[[@B21]\]. There were studies explaining an association between irradiation and an increase in risk of distant recurrence by alteration of cancer cells phenotype and an increase in breast cancer stem cells (BCSC) causing cancer cells more aggressive \[[@B22]--[@B24]\]. Recently, one study proposed an increase in awareness of irradiation in patients with early stage breast cancer \[[@B25]\]. In the present study, after exclusion of patients with stage 3 (to whom radiation was routinely recommended), analysis in only patients with stages 1 and 2 demonstrated that radiation therapy increased the hazard of distant recurrence (HR = 3.83, 95%  CI = 2.15--6.80,  *P* \< 0.001). Although the present study agreed with the aforementioned study, many previous studies reported the opposite findings that irradiation reduced the risk of recurrence \[[@B3]\] and spreading to other organs \[[@B26]\].

### 4.2.4. Hormonal Therapy {#sec4.2.4}

The most common hormone therapy, tamoxifen, is a competitive partial agonist-inhibitor for estrogen receptor located on cancer cells. Its effect on cell proliferation inhibition results in a reduced risk of dissemination to other organs \[[@B27]\].

4.3. Prognostic Characteristics for Death from Cancer {#sec4.3}
-----------------------------------------------------

Patients who died of breast cancer were caused by consequences of distant recurrence or metastasis \[[@B19]\]. It could also be restated that distant recurrences are the surrogates of death \[[@B26]\].

### 4.3.1. Pathological Tumor Size \>2 cm {#sec4.3.1}

Tumors larger than 2 cm were more likely to spread to adjacent lymph nodes, increasing the chance of spreading to other organs \[[@B28]\], which led to an increasing risk of death.

### 4.3.2. Stage 3 and Positive Axillary Lymph Nodes \>3 {#sec4.3.2}

This could be due to the common findings that stage 3 and positive axillary lymph nodes \>3 increase the chance of spreading to distant organs, which is the cause of death.

### 4.3.3. Presence of LVI {#sec4.3.3}

Direct spreading to lymph vessels increased the chance of spreading to other organs \[[@B29]\]. There were studies that confirmed such association \[[@B30]\].

### 4.3.4. Hormonal Therapy {#sec4.3.4}

As mentioned above, treatment with tamoxifen reduced the chance of spreading to distant organs \[[@B27]\], resulting in a reduced hazard of death.

### 4.3.5. Chemotherapy Therapy {#sec4.3.5}

Most chemotherapy was aimed at micrometastatic cell. This action reduced tumor cell dissemination to distant organs which was the cause of death \[[@B31], [@B32]\].

In summary, the prognostic characteristics for breast cancer recurrence and death reported in the present study were mostly similar to previous reports \[[@B9], [@B10]\]. However, it should be noticed that the effect of radiation therapy was unexpectedly opposite. It could be argued that this was likely due to the "confounding by indication" effect. Nevertheless recent animal studies and reports in human are discussing the probability that irradiation of tumor cells stimulates breast cancer stem cell (BCSC) to proliferate and form radioresistance \[[@B22]\]. At present, there are no researches conducted in human to clarify this hypothesis. The present study may be one of the earliest observational reports on this finding. Whether radiation therapy is beneficial to breast cancer patients remains the subject of further researches in the future.

5. Conclusions {#sec5}
==============

Evidences of tumor cells invasions, positive axillary lymph nodes \>3 and presence of LVI, increased the risk of locoregional recurrence. The same evidence, disease stage 3 and positive axillary lymph nodes \>3, increased the risk of distant recurrence, while hormonal therapy reduced the risk. The risk of death from cancer was increased in pathological tumor size \>2 cm, disease stage 3, positive axillary lymph nodes \>3, and presence of LVI, while hormonal therapy and chemotherapy therapy reduced such risk. The effect of radiation is inconclusive but may increase the risk of distant recurrence.

The authors declare that they have no conflict of interests.

The authors wish to thank the authorities of Lampang Hospital and Uttaradit Hospital for permission on data retrieval and support. The study was partially supported by the Basic and Applied Sciences Research Grant from the Faculty of Graduates, Chiang Mai University.

###### 

Clinical profiles and treatment of breast cancer (*n* = 829), by first occurring events.

  Characteristics                               Recurrence               *P* value               
  -------------------------------- ----- ------ ------------ ------ ---- ----------- ---- ------ ---------
  Age (year)                                                                                      
   ≤45                             166   26.1   25           30.1   30   38.5        4    12.9   0.030
   \>45                            471   73.9   58           69.9   48   61.5        27   87.1    
  Types of surgery                                                                                
   MRM                             543   85.2   72           86.8   70   89.7        26   83.9   0.120
   Simple mastectomy               40    6.3    9            10.8   5    6.4         4    12.9    
   BCS                             54    8.5    2            2.4    3    3.9         1    3.2     
  Pathological tumor size (cm)                                                                    
   ≤2                              272   42.7   23           27.7   16   20.5        10   32.3   \<0.001
   \>2                             365   57.3   60           72.3   62   79.5        21   67.7    
  Histological type                                                                               
   Ductal carcinoma                590   92.6   82           98.8   77   98.7        30   96.8   0.191
   Lobular carcinoma               5     0.8    0            0.00   0    0.00        0    0.00    
   Other types                     42    6.6    1            1.2    1    1.3         1    3.2     
  Histological grade                                                                              
   I                               110   19.2   8            9.9    9    12.0        2    7.4    0.027
   II                              280   48.9   46           56.8   38   50.7        9    33.3    
   III                             183   31.9   27           33.3   28   37.3        16   59.3    
  Stage                                                                                           
   1                               218   34.2   16           19.3   9    11.5        3    9.7    \<0.001
   2                               353   55.4   43           51.8   41   52.6        22   71.0    
   3                               66    10.4   24           28.9   28   35.9        6    19.3    
  Dissected axillary lymph nodes                                                                  
   \<10                            125   20.3   20           25.6   17   23.0        7    24.1   0.641
   ≥10                             490   79.7   58           74.4   57   77.0        22   75.9    
  Positive axillary lymph nodes                                                                   
   ≤3                              530   86.0   42           53.9   38   51.4        20   69.0   \<0.001
   \>3                             86    14.0   36           46.1   36   48.6        9    31.0    
  LVI                                                                                             
   Absent                          377   60.1   23           29.5   22   29.0        11   36.7   \<0.001
   Present                         250   39.9   55           70.5   54   71.0        19   63.3    
  Receptor status                                                                                 
   ER receptor                                                                                    
    Positive                       398   63.6   44           55.0   36   47.4        20   66.7   0.027
    Negative                       228   36.4   36           45.0   40   52.6        10   33.3    
   PR receptor                                                                                    
    Positive                       351   56.0   42           52.5   30   39.5        18   60.0   0.047
    Negative                       276   44.0   38           47.5   46   60.5        12   40.0    
   HER2 receptor                                                                                  
    Positive                       236   40.5   38           54.3   35   49.3        11   39.3   0.093
    Negative                       347   59.5   32           45.7   36   50.7        17   60.7   
  Treatment                                                                                       
   Radiotherapy                                                                                   
    Yes                            199   31.3   41           49.4   52   66.7        8    26.7   \<0.001
    No                             436   68.7   42           50.6   26   33.3        22   73.3    
   Hormonal therapy                                                                               
    Yes                            418   65.6   48           57.8   38   48.7        23   74.2   0.011
    No                             219   34.4   35           42.2   40   51.3        8    25.8    
   Chemotherapy                                                                                   
    Yes                            547   86.3   80           96.4   73   93.6        19   63.3   \<0.001
    No                             87    13.7   3            3.6    5    6.4         11   36.7    

MRM: modified radical mastectomy; BCS: breast-conserving surgery; LVI: lymphovascular invasion; ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2.

###### 

Effect (hazard ratio, HR) of clinical profiles and treatment on locoregional recurrence, distance recurrence, and death in breast cancer (*n* = 829), univariable analysis.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Prognostic factors                             Locoregional recurrence   Distant recurrence   Death                                               
  ---------------------------------------------- ------------------------- -------------------- -------------------- ---------- ------------------- ---------
  Age (year)                                                                                                                                         

   \>45 versus ≤45                               0.91 (0.57--1.46)         0.696\               0.64 (0.44--0.94)    0.022\     1.01 (0.69--1.49)   0.942\

  Types of surgery                                                                                                                                   

   Simple mastectomy and BCS versus MRM          0.85 (0.62--2.21)         0.609                1.41 (0.73-- 2.70)   0.305      1.08 (0.62--1.88)   0.792

  Pathological tumor size (cm)                                                                                                                       

   \>2 versus ≤2                                 1.85 (1.14--2.99)         0.012\               1.99 (1.30--3.04)    0.001\     2.12 (1.42--3.16)   \<0.001

  Histological type                                                                                                                                  

   Ductal CA versus lobular CA and other types   5.04 (0.70-- 36.19)       0.108                3.32 (0.82--13.44)   0.093      2.40 (0.76--7.54)   0.135

  Histological grade                                                                                                                                 

   II and III versus I                           2.21 (1.06--4.59)         0.033                1.84 (1.01--3.35)    0.047      2.04 (1.15--3.63)   0.015

  Stage                                                                                                                                              

   3 versus 1 and 2                              3.56 (2.21--5.75)         \<0.001              5.06 (3.43--7.46)    \<0.001    4.53 (3.14--6.52)   \<0.001

  Dissected axillary lymph nodes                                                                                                                     

   ≥10 versus \<10                               0.81 (0.49--1.34)         0.408\               0.86 (0.55--1.35)    0.514      0.81 (0.54--1.21)   0.297

  Positive axillary lymph nodes                                                                                                                      

   \>3 versus ≤3                                 4.53 (2.89--7.10)         \<0.001              4.93 (3.35--7.27)    \<0.001    4.85 (3.39--6.92)   \<0.001

  LVI                                                                                                                                                

   Present versus absent                         3.42 (2.11--5.58)         \<0.001              3.66 (2.40--5.59)    \<0.001    4.35 (2.88--6.57)   \<0.001

  Receptor status                                                                                                                                    

   ER receptor                                                                                                                                       

    Negative versus positive                     1.49 (0.96--2.31)         0.079                2.05 (1.40--2.99)    \<0.001    1.64 (1.15--2.34)   0.006

   PR receptor                                                                                                                                       

    Negative versus positive                     1.24 (0.80--1.92)         0.339                1.84 (1.25--2.71)    0.002      1.57 (1.10--2.24)   0.012

   HER2 receptor                                                                                                                                     

    Negative versus positive                     0.60 (0.37--0.96)         0.033                0.89 (0.60--1.32)    0.553      0.80 (0.55--1.15)   0.225

  Treatment                                                                                                                                          

   Radiotherapy                                                                                                                                      

    Yes versus no                                2.17 (1.42--3.35)         \<0.001              4.35 (2.93--6.47)    \<0.001\   2.72 (1.91--3.86)   \<0.001

   Hormonal therapy                                                                                                                                  

    Yes versus no                                0.64 (0.41--0.99)         0.044                0.45 (0.31--0.65)    \<0.001    0.58 (0.41--0.82)   0.002

   Chemotherapy                                                                                                                                      

    Yes versus no                                3.78 (1.19--11.96)        0.024                2.99 (1.22--7.34)    0.017      0.97 (0.57--1.64)   0.907
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

MRM: modified radical mastectomy; BCS: breast-conserving surgery; LVI: lymphovascular invasion; ER: estrogen receptor; PR: progesterone receptor; HER2: Human Epidermal Growth Factor Receptor 2.

###### 

Effect (hazard ratio, HR) of clinical profiles and treatment on locoregional recurrence, distance recurrence, and death in breast cancer (*n* = 829), multivariable analysis (reduced model).

  Prognostic factors              Locoregional recurrence   Distant recurrence   Death                                              
  ------------------------------- ------------------------- -------------------- ------------------- --------- -------------------- ---------
  Age (year)                                                                                                                         
   \>45 versus ≤45                1.07 (0.64--1.78)         0.801                0.75 (0.50--1.13)   0.164     0.93 (0.62--1.40)    0.722
  Pathological tumor size (cm)                                                                                                       
   \>2 versus ≤2                  1.46 (0.87--2.45)         0.148                1.26 (0.80--1.97)   0.316     1.56 (1.02--2.40)    0.040
  Stage                                                                                                                              
   3 versus 1 and 2               1.65 (0.94--2.91)         0.081                2.44 (1.57--3.80)   \<0.001   2.17 (1.42--3.32)    \<0.001
  Positive axillary lymph nodes                                                                                                      
   \>3 versus ≤3                  2.43 (1.35--4.37)         0.003                1.79 (1.10--2.93)   0.020     2.16 (1.36--3.43)    0.001
  LVI                                                                                                                                
   Present versus absent          2.01 (1.09--3.71)         0.026                1.64 (0.96--2.83)   0.073     2.87 (1.69--4.87)    \<0.001
  Treatment                                                                                                                          
   Radiotherapy                                                                                                                      
    Yes versus no                 0.90 (0.54--1.53)         0.709                2.40 (1.50--3.84)   \<0.001   1.32 (0.86-- 2.03)   0.201
   Hormonal therapy                                                                                                                  
    Yes versus no                 0.70 (0.44--1.11)         0.128                0.44 (0.30--0.65)   \<0.001   0.57 (0.40--0.83)    0.003
   Chemotherapy                                                                                                                      
    Yes versus no                 1.51 (0.45--5.02)         0.502                1.36 (0.41--4.49)   0.612     0.27 (0.14--0.52)    \<0.001

LVI: lymphovascular invasion.

###### 

Summarized direction of significant prognostic hazards (locoregional recurrence, distance recurrence, and death in breast cancer).

  Prognostic factors                  Prognostic hazards              
  ----------------------------------- -------------------- ---------- ----------
  Pathological tumor size \>2 cm                                      Increase
  Stage 3                                                  Increase   Increase
  Positive axillary lymph nodes \>3   Increase             Increase   Increase
  LVI present                         Increase                        Increase
  Treatments                                                           
   Radiotherapy                                            Increase    
   Hormonal therapy                                        Decrease   Decrease
   Chemotherapy                                                       Decrease

LVI: lymphovascular invasion.
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